Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Subacute cutaneous lupus erythematosus (SCLE) is a form of cutaneous lupus erythematosus (CLE) that can present either as a non-scarring, annular photo-distributed dermatosis or psoriasiform plaques. SCLE is associated with anti-Ro/SSA antibodies and can be drug-induced.
Biomarker and diagnostic research for subacute cutaneous lupus erythematosus has been reported in the published literature.
8 clinical trials registered, 2 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE4, 4 PHASE3, 2 PHASE2. Research is primarily industry-sponsored.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06044337](https://clinicaltrials.gov/study/NCT06044337) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 1:11 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
PHASE3 |
Biogen |
ENROLLING_BY_INVITATION |
[NCT06980805](https://clinicaltrials.gov/study/NCT06980805) | A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) | PHASE2 | Immunovant Sciences GmbH | ACTIVE_NOT_RECRUITING |
[NCT06013995](https://clinicaltrials.gov/study/NCT06013995) | A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus | PHASE1 | Bristol-Myers Squibb | UNKNOWN |
[NCT06875960](https://clinicaltrials.gov/study/NCT06875960) | A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 | PHASE4 | Bristol-Myers Squibb | RECRUITING |
[NCT07355218](https://clinicaltrials.gov/study/NCT07355218) | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) | PHASE3 | EMD Serono Research & Development Institute, Inc. | RECRUITING |
54 publications have been identified in PubMed for subacute cutaneous lupus erythematosus. Research spans Case Report / Case Series (75%), Epidemiology / Natural History (8%), and Other (6%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 39 | 75% |
Disease patterns and progression | 4 | 8% |
Other research | 3 | 6% |
Clinical study results | 3 | 6% |
Testing and diagnosis research | 1 | 2% |
Research summaries | 1 | 2% |
Laboratory research | 1 | 2% |
Gachiniard E (2026). [PMID: 42191551](https://pubmed.ncbi.nlm.nih.gov/42191551/). *Therapie*. [Other]
Aida Y (2026). [PMID: 42033659](https://pubmed.ncbi.nlm.nih.gov/42033659/). *Int J Rheum Dis*. [Other]
Kenney S (2026). [PMID: 42115135](https://pubmed.ncbi.nlm.nih.gov/42115135/). *J Cutan Pathol*. [Case Report / Case Series]
Clifford T (2026). [PMID: 42114565](https://pubmed.ncbi.nlm.nih.gov/42114565/). *Vet Dermatol*. [Basic Science / Preclinical]
Lu YY (2026). [PMID: 41117372](https://pubmed.ncbi.nlm.nih.gov/41117372/). *The Journal of dermatology*. [Case Report / Case Series]
Smith K (2026). [PMID: 41675029](https://pubmed.ncbi.nlm.nih.gov/41675029/). *JAAD case reports*. [Case Report / Case Series]
Choi K (2026). [PMID: 42005202](https://pubmed.ncbi.nlm.nih.gov/42005202/). *Cureus*. [Case Report / Case Series]
Lee CH (2026). [PMID: 42140364](https://pubmed.ncbi.nlm.nih.gov/42140364/). *J Am Acad Dermatol*. [Review / Meta-Analysis]
Alicea DS (2025). [PMID: 40661107](https://pubmed.ncbi.nlm.nih.gov/40661107/). *JAAD case reports*. [Case Report / Case Series]
Henson BD (2025). [PMID: 39807367](https://pubmed.ncbi.nlm.nih.gov/39807367/). *JAAD case reports*. [Case Report / Case Series]
AI-curated news mentioning subacute cutaneous lupus erythematosus
Updated Mar 30, 2026
Biogen's drug for cutaneous lupus erythematosus shows promising results in reducing disease activity, marking a significant advancement in their immunology and inflammation pipeline. Analysts view this as a crucial derisking step for the company's future prospects.